MOCS3

Across TCGA pan-cancer cohorts, MOCS3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MOCS3 data layer compared with 24 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MOCS3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MOCS3 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, LSCC, and LUAD are the cancer types where MOCS3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.514	0.288	.001	62	view →
LSCC	OS	Quartile	III,IV	0.487	0.933	.007	16	view →
LUAD	OS	Tertile	All	1.000	0.955	.014	14	view →
HNSC	OS	Tertile	II,III,IV	0.923	1.000	.018	12	view →
CCRCC	DFS	Median	III,IV	0.818	0.244	.031	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MOCS3–PDAC (DFS)

Open the PDAC breakdown →